Okay, it looks like, we've got a good number of people in here now. I'll pass things over to Robert Kaul, CEO of Cloud DX, to kick off today's presentation. Good afternoon, everyone. Thank you, and welcome to our January investor webinar. It's a great pleasure to be able to talk to you all about Cloud DX and our performance last year, and also some insight into how 2024 is starting to look. So I'm gonna ask for the next slide. Please remember that we may discuss forward-looking statements today. This disclaimer is in our investor deck, and if you have any questions about forward-looking statements, please take a look at this disclaimer. So Cloud DX, for those who are not perfectly familiar with us, is a technology leader in the field of remote patient monitoring and virtual healthcare. We are coming up on our tenth anniversary in 2024, founded in Canada. Today, what we're gonna announce, what we're gonna discuss today rather, is some of the recent announcements that we've made since the beginning of 2024. We're gonna put those into the context of some of the work we've done and the announcements we've made in previous months and in previous quarters. Then towards the end of the presentation, we'll be able to take questions using the question tool in Zoom here today. We are recording this webinar, and it will be available on our website as soon as we've completed it and had it edited. If we don't get to your questions today for whatever reason, please email our questions or we will email you back, and to make sure all of our questions are answered by the end of the week. Really, quite frankly, we're very excited. Cloud DX's technology platform is a complete end-to-end platform that delivers virtual care in Canada and the United States, with potential growth all over the world. We are the leader in Canada, in this part, in this part of the technology world, and highly competitive, highly differentiated, as we'll see as we go through. I will be discussing in detail what our products are and what they do. Again, for those of you who are not perfectly familiar, we'll get into the details of exactly how Cloud DX technology actually works. One of the most important things that differentiates Cloud DX from other companies in our space is our partnerships, and I get a lot of questions from investors about what these partnerships actually entail. Sometimes the word partnership isn't necessarily a, you know, a two-way street. Sometimes it seems like it really just gives you the right to buy stuff from a partner, but that's not the way, Cloud DX partnerships work. We are co-marketing and co-distributing with our partners. They are helping us build our business as we help them build their business. They are driving sales and increasing revenue every quarter. We are FDA cleared and registered. We are SOC 2 compliant for privacy and security, and we're Health Canada licensed as a medical device manufacturer. We have a medical device establishment license and as a software developer. Next slide. So, many of you may have seen our previous earnings calls, and we're happy to say that the numbers from 2023 were extremely good. And, these are the most important numbers we want to share today. Of all the numbers we're gonna talk about today, subscription revenue up 75.4% is by far the most important. Cloud DX operates a software-as-a-service, subscription-based business that is augmented by the sale of connected devices and hardware and by services and integrations and customizations, and those are the three areas of revenue you see in our financial statements. In general, 2023 has been an extremely good year. Gross profits are up 52%. More importantly, our Adjusted EBITDA improved in the third quarter by 47.5%, and of course, the year-end is not finished yet, but the trajectory has been established. Next slide. But 2024 has started off on an incredible note. Since January first, Cloud DX has made announcements around five contracts so far. The total value of these contracts is over CAD 1.8 million. Health PEI is the first announcement we made in January, on January second. This is our fourth territorial or provincial-level contract in Canada. It's a long-term contract that was signed under our Mohawk Medbuy master agreement, and our Mohawk Medbuy relationship is extremely important. In the summer of last year, we announced that we had been chosen in a competitive RFP as the sole vendor for the largest hospital procurement agency in Canada. That means that over 100 hospital systems and provinces can simply order Cloud DX technology directly from Mohawk Medbuy. This is one of those transactions, and the value of that contract is front-loaded with the purchase of connected health devices, which we'll discuss in just a couple of minutes. Then the remainder is subscription revenue that can actually continue over up to seven years. Now, I want to emphasize that this is the beginning of a contract relationship with Health PEI. In general, with our other contracts of this kind, the contracts expand and grow as new use cases and new patients are onboarded. The contract on January ninth, we announced, is actually really exciting. It's a one-time... Again, the beginning of a relationship, but it's the one—it's a one-time contract, CAD 115,000, to design and use our intellectual property in a new way. All of this money will hit in the first and second quarters of 2024. Then we were very pleased to announce three new contracts just last week. And these include the extension of our longest-running contract with Markham Stouffville Hospital. We first began doing business with Markham Stouffville all the way back in 2017, and that's a perfect example of a client of Cloud DX who continues to extend and expand their contract and add new use cases and new patients to the platform. That extension is for 36 months, taking it all the way out to 2026. The other two contracts announced were for family health teams in Ontario for palliative care use cases, which is one of nearly a dozen use cases now for Cloud DX technology across North America. This is just the first 2.5 weeks of the month. We're having an extremely interesting and exciting ramp-up here, and investors should please pay attention because there are additional announcements still coming. Next slide. This really does show the growth of Cloud DX in the last couple of years. So we created this slide just to really tie together the important aspects of the growth in our contracts and the growth in patients enrolled, and they are following each other up as this climbs and climbs and climbs. So, this shows that patients enrolled now are approaching 6,000, and more importantly, what we're seeing here is roughly a double every year so far. But as you'll see, with the size of these contracts we're announcing, that pace is accelerating. Next slide. So I promised to talk a little bit more about what exactly Cloud DX offers, and our product platform consists of these three parts. The Connected Health Kit is a kit of medical devices and tablet computers that are used by patients in their homes to monitor their vital signs, to communicate with their care team by a two-way text messaging and by video, to answer survey questions, and in all ways, basically, to extend the care of the hospital or the doctor's office into the home. One of the new use cases we're addressing is something called Hospital at Home, where people are being discharged earlier and earlier from hospital to the home environment and monitored at home as if they were in the hospital, which is an extremely efficient use of resources, and of course, everyone wants to be home as soon as possible. The subscription part of our business is a SaaS model on a per-patient, per-month basis. That includes a portal that clinicians use to monitor our technology, to monitor their, their patients, rather. The patient app and all the two-way connectivity and all the two-way communication between the two. And then the third part of our business is the service and integrations part. This part of our business is growing rapidly. The larger contracts that we sign with the larger health authorities, like Alberta Health Services, the Alberta Primary Care Networks, and others, mean that we're doing more and more integrations into large-scale Electronic Medical Record systems, and we charge time and materials for all of these integrations. So this is the platform we're currently in market with. Next slide. And these are the technologies we're bringing to market in the next several quarters. Cloud DX is differentiated as an innovator with a tremendous amount of intellectual property that has now become commercialized. The first note here is our Pulsewave wrist cuff, which is a new way of measuring blood pressure and respiration rate, patented. The second device in the—on the screen here is our Vitaliti Continuous Vital Sign monitor. This monitor is destined to be used in a 20,000-patient, multi-site clinical study. And the third unit here, the third, technology, rather, this is our Accuscreen cough analysis application. This is AI-powered software that's capable of detecting the sound of a person coughing and identifying the respiratory disease that's causing their cough. This technology is also patented. It's in large-scale field studies right now in Africa for tuberculosis. And I really need to point out, a competing technology was acquired by Pfizer about a year and a half ago for $116 million, and that technology was not any further commercialized than ours. This intellectual property forms the basis of Cloud DX's value and is not necessarily reflected in our balance sheet just yet. Next slide. I really want to emphasize, with all the attention being paid right now to artificial intelligence and generative AI, that Cloud DX has been an AI company since 2017. Next slide. We have 14 patents, and you'll see if many of those are AI patents. We've created, as you saw on the previous slide, a 3D augmented reality user interface, which is now getting closer and closer to deployment in the United States. Peer-reviewed papers about our technology have been published in some of the most prestigious medical journals in the world, including the British Medical Journal, and Cloud DX has received over CAD 18 million in non-dilutive grant funding to further this AI-based R&D. And I've already brought up the, the multi-site study that's coming for Vitaliti. Next slide. So we're really pleased to announce that our most recent AI patent was granted to us just yesterday. That is our fourteenth patent, and it's a patent that applies to our Vitaliti technology and its ability—the software's ability to detect and monitor medication adherence and medication effectiveness. So eight artificial intelligence patents, three medical device patents, and three data analytics patents form the basis of Cloud DX's IP so far. Further patents pending are coming. Next slide. So let's tie together now, what is the value proposition? Why are sales growing so quickly? What is it about virtual care and remote monitoring that is driving this change in the healthcare system? And the bottom line is that it's better for virtually everyone. Patients benefit because they get to go home from hospital sooner, they recover from their surgery faster, their long-term chronic illnesses are less likely to send them back to hospital, and the satisfaction scores and compliance scores reflect that. Providers, that is, doctors, nurses, get to care for more patients with the same resources. Their jobs are more efficient, and their jobs get easier by using virtual care and the software behind it that automates a lot of their work. It makes it easier and easier to care for the patients who are the sickest, while the patients who need less attention are literally automatically cared for by the technology. Payers, in the Canadian context, that's the government, in the U.S. context, it's insurance companies, it's Medicare and Medicaid services. The benefit of this care is simply that it's more efficient. You get a bigger bang for your buck, and in the United States, it directly drives reimbursement and new dollars for providers. Next slide. So that's why virtual care. But why Cloud DX? And these are the reasons why. We are the most innovative in our space. These new technologies I've described, our IP portfolio, our published papers, reflect the innovation that we're driving, and what that drives is, in fact, drives sales. And the way that works is quite simple. When we are addressing our clientele at the sales stage, being able to describe what's coming in the pipeline and talking about the new technologies we're bringing to market in the next several quarters, essentially makes us future-proof. It means that we're the ones who are bringing change, we're the ones who are delivering the next innovation, and our clients are first movers. That means we make them more competitive, and, there's nothing, better than you can do that for your, for your customers. From the point of view of compliance, which means patients doing what they're, they're meant to do by their care team, Cloud DX satisfaction scores and compliance scores are the highest in the industry, over 95%. This drives not only adoption, and it drives enrollment of patients, it's also a strong competitive advantage. And the last point, again, just coming back to our partnerships and just reiterating that our partnerships with Teladoc and Medtronic, with Mohawk Medbuy and academic partnerships, like the one we have with the Population Health Research Institute and McMaster, these are distribution partnerships, they're sales partnerships, or they're academic studies that drive non-dilutive R&D funding and in some cases, large-scale deployment. Population Health Research is part of the same hospital group as Hamilton Health Sciences, the largest client of Cloud DX in Canada. That relationship is a synergistic relationship, and in fact, it has resulted in the first command center for Remote Patient Monitoring that's set up and actually live and active today at Hamilton Health Sciences. That is driving not only all the virtual care in a three-hospital system run on Cloud DX, but also the academic work being done by the scientists on the other side. These, these, these partnerships are driving revenue. In 2023, Cloud DX became the undisputed market leader in remote monitoring and virtual care in Canada. We've won 8 out of the last 9 competitive RFPs or tenders. We now have, by far, the largest footprint in the country. As I mentioned earlier, we are already partners for vendors, sole vendors, under long-term government contracts to four provinces or territories. And then we have coverage across the entire country through our sole source vendor status with Mohawk Medbuy, the largest procurement agency in the country. Next slide. But in the United States, we're also growing very quickly. We already have paying contracts in four states. So that's Massachusetts, Pennsylvania, Michigan, and Oregon, and relationships in California, relationships in Florida. Additional growth is coming in the United States. It's a complicated market, but there is no giant market leader in the U.S. There's no one big 800-pound gorilla that controls the market in any way. There are lots and lots and lots of little companies that are fairly local in their outreach. We are targeting from our strengths, based on our Canadian experience and our experience scaling into some of the largest healthcare systems in North America. Alberta Health Services is a perfect example. That experience of operating at scale is actually quite unusual, and it gives us a huge competitive advantage with the larger potential customers we're talking to in the United States. Next slide. Now, we've mentioned earlier that Cloud DX has won many awards, and I wanted to emphasize two things. First of all, some of the larger, more important awards that we've won over the years come with non-dilutive funding that, to this day, is still powering some of the Cloud DX research and commercialization push that's being done. We're the first Canadian company to ever win an XPRIZE. That came with a long-term relationship with the University of California, San Diego, millions of dollars in non-dilutive funding, and that funding is still paying for research we're doing, for example, on cough analysis in Africa. As you see here, Fast Company World Changing Idea. We won a $100,000 grant, co-winner of that grant with PHRI, Population Health Research, and so on. That's important. The accolades are nice, but more importantly, the non-dilutive cash adds value for investors. Next slide. So coming now to our cap table, Cloud DX is tightly held by our a group of insiders, four board members, founders. Over 44% of Cloud DX now is owned by insiders, which is an increase since we went public in 2021. No insider at Cloud DX has ever sold a share. At each of our funding rounds, the majority of the funding is purchased by insiders and colleagues and their circle. And that means that we have a very deep bench of very, very, long on our story, investors who are, in fact, continuing to invest in Cloud DX every chance they get. And you'll see that when you look at the insider buying patterns on, sedi.com or sedi.ca. Next slide. So before we take questions, I'm gonna wrap this up now by answering this question: Why invest in Cloud DX and why invest now? We are seeing demand skyrocket. Across Canada, provinces, hospital systems have awarded the RFPs. The announcements have been made or are still coming, but the investment in virtual care has been earmarked and is now rolling out in 2024. That means the patient enrollment numbers for Cloud DX as the, by far the largest now embedded RPM vendor in Canada, are now growing at an even more accelerated rate. Cloud DX has the most validations, the most published papers, the strongest patent portfolio, the highest compliance scores, the highest satisfaction scores. All of this drives sales. All of this is very strong competitive advantage. Helps explain why Cloud DX, even against much larger companies, continues to win RFP and tender after RFP and tender. But if there's one thing I want investors to take away from this entire webinar today, the most important point I can make today is that our subscription revenue is up 75%. Yes, the revenue from hardware and the revenue from our Connected Health Kit s that are purchased at the beginning of each large contract is also, of course, driving EBITDA. Yes, services and integrations is a growing section of our business, but both of those support recurring revenue. They support the subscription revenue from ever larger number of patients using Cloud DX. That number is accelerating. It's driven not only by our own efforts, but by the efforts of the largest partners we could possibly have, partners like Medtronic, partners like Teladoc, and others. And so where Cloud DX is at now is a point where growth has been proven, the contracts are awarded, the technology has matured, the patents have been granted, and now what investors are gonna see is, I think, quite frankly, a revolution in virtual care in the next two to three years. Okay, thank you very much. Last note before we move on, we're very pleased to be chosen to speak at or present at a number of conferences in the next couple of months. These are two that are available, I think, for investors to actually access. We're speaking at the Maxim Group Virtual Healthcare Conference on January 24th, 9:30 A.M., and if you just go to our website, we have a list of these conferences coming. You can click the link, you can sign up, and we'll be able to talk more about whatever's been announced and whatever's changed between now and January 24th. And then we're also speaking at the MicroCap Conference, which is one of the largest MicroCap conferences in North America, being held in Atlantic City in February or late January. Okay, I'm gonna now move to the questions. I'm gonna go ahead and... Let's see here, questions coming in. This is a good question. Why fully diluted shares have been, you know, are at a higher number than the issued and outstanding shares? So the easy answer to that question is, and if you look back on our press releases, you'll see that Cloud DX, since we went public in 2021, has done. The majority of the private placements we've done have been convertible notes or convertible debt. So that, of course, is referenced in our cap table as not issued shares yet, but as part of our fully diluted shares. As those notes mature and as they convert into shares, you will see, of course, that number start to even out and the issued shares and the issued shares will go up and the non-issued shares will come down. But I want to emphasize, the majority of those shares are owned by insiders and colleagues. They're owned by folks who are long on our story. No insider has ever sold a share of Cloud DX. So what you're not gonna see is you're not gonna see a large number of shares come on the market and have to find a buyer and flip over before and, you know, as those loans mature. What you should expect to see is insiders converting their notes into shares and holding, as they've done since we went public. Here we go. Well, this is an interesting question. If Cloud DX is such a strong candidate, and we believe we are, why has the stock price not increased? That is a very good question. I think part of the reason we're doing this webinar, and part of the reason we are getting the word out about Cloud DX, is that the whole market is really just not paying attention to this sector at the moment. One of the ways we can change that is by continuing to grow as fast as we can. Another way is by getting the word out that Cloud DX has reached this inflection point where the things stopping us from growing now have really been de-risked. Another terrific question that comes from a long-term investor at Cloud DX: What are the options-- What are the obstacles, rather, to actually getting patients signed up? How many patients do we need to get to cash flow positive or to break even? When we sign a contract with a hospital system or a large physician practice, the stages of that contract are relatively simple. After the contract's signed, we need to train and onboard the staff, and in some cases, integrate with the Electronic Medical Record system, but not every case. Then once that happens, we can then begin to onboard patients and see patients join the system. Back in 2021 and 2022, early 2022, this process was quite laborious. But we've recently hit on some interesting innovations, 'cause we're a very innovative company. We actually call this Patient-First Onboarding. It's a differentiator for Cloud DX, and what it allows us to do is embed Cloud DX staff with the client at the very beginning to not only onboard the first group of patients as fast as possible, but also at the same time, train the staff, and then support them virtually from that point onwards. So we have started to really see onboarding of patients accelerate. I can say that in one of, you know, one of our more recent days, this month, in January, we onboarded over 30 patients. The answer as to how many patients we need to reach cash flow positive, depends on a couple of other factors. When you think about the revenue mix at Cloud DX, when you think about the recurring revenue, but also ongoing revenue from the other sources of revenue we have, cash flow positive is a combination of all those things. But we've often said in previous communications that in the neighborhood of 10,000 patients on our system is at the point where we start to see recurring revenue... You know, basically paying the bills. And if you go back to that slide that we looked at earlier, you'll see at the end of 2023, we were approaching 6,000 patients. So are we about halfway there? I think that's a reasonable assumption. And because the pace of onboarding is accelerating, we feel that cash flow positive is getting closer and closer. That, in fact, is evidenced by the nearly 50% drop in Adjusted EBITDA or improvement rather than Adjusted EBITDA. Basically, we cut our losses in half, and that's September's numbers. That's not the full year's numbers. So the story, as evidenced in our financial statements, just keeps getting better. An interesting question about some of the convertible notes, and I'm gonna hit on this question because it's a question that might pop up in other, other investors' minds as well. Cloud DX was offering an attractive interest rate on our convertible notes, and the reason we were able to do that is because we entirely self-directed those private placements. Most of the time, companies like Cloud DX wind up paying quite substantial finder's fees to brokers and dealers who help them find investors. Typically, 8% cash and 8% in stocks or warrants. But if you look at our press releases, you'll see we paid almost no finder's fees and almost no broker's fees for the CAD 6.5 million we raised last year in convertible notes. What we were allowed to do then is basically offer that back to the investors. And because our investors are insiders, colleagues, for the most part, it's a chance to make sure that those investments met our goals. But keep in mind that we did not pay finder's fees, and we did not pay broker's fees on that CAD 6.5 million, except for a very small percentage. Okay, great question. Does Cloud DX do real-time monitoring or just deliver data to the carrier? Now, when you think about remote patient monitoring, there's two kinds of monitoring. We call Spot Monitoring just taking a blood pressure reading or just taking a pulse ox reading. That's a reading in time. It's gathered by our system automatically, it's scanned by our software, it's sent directly to the dashboard, and at that point, it may or may not generate a notification to the care team that something is amiss and that they need to pay attention to that patient. Continuous Monitoring is new devices like our Vitaliti device, that has a continuous stream of data. In the case of Vitaliti, it's ECG data, it's pulse oxygen data, accelerometers, gyroscopes, and continuous non-invasive blood pressure. Not every patient needs continuous monitoring all the time. One reason we're embarking on a very large, very prestigious study in order to determine how much continuous monitoring impacts patient outcomes of post-surgical patients, is to publish peer-reviewed papers on exactly how that next needs to work. But Cloud DX is a pioneer in continuous monitoring. Another example is our Continuous Connected Patient Care project. This is a project that was announced in November of 2022 with Medtronic. We are integrating a new continuous monitor from Medtronic into the Cloud DX dashboard, and once that integration is complete in 2024, Medtronic and Cloud DX together will be marketing that platform all over the world. So I can confidently say we are leading the charge when it comes to not only how to do continuous monitoring, but when to do continuous monitoring. That was a great question. So here's an interesting question. Primary care demands are skyrocketing with an aging population in chronic disease management. Many providers need efficiency and automation. What strategies can we expect from Cloud DX that can make primary care faster, better, cheaper, and more automated? So for those investors who are not completely up on the different kinds of care, primary care means basically when you go to see the doctor at the doctor's office or when you go to a walk-in clinic or when you go to the emergency room for a non-life-threatening event. This is the primary source of care for most Canadians, and in fact, most North Americans. It's a place where we've all heard the stories, we've all seen the news reports, ER shutting down, stressed out clinicians, stressed out physicians, wait times that are now stretching into the days, waiting in the ER for service. So how can we make this better? Cloud DX, again, is a pioneer in this, and in our largest deployments across Canada, like in Alberta and like in Ontario, with many of our clients in Ontario, what you're seeing is the virtualization of primary care. What that means is that clients come into the ER, and rather than having to wait to be admitted, they're literally processed, given a Connected Health Kit from Cloud DX, and sent home. And now they can be cared for remotely. The software takes the burden. We're able to automate and improve the patient experience and reduce the amount of stress on the ER. On the other side, when you are able to release that surgical patient home 1.9 days earlier than you were before, which is a reported number from Hamilton Health Sciences, that means you've freed up the bed. It means that you can now admit many more patients from the ER faster. You've re-reduced that pressure. So these are the ways that Cloud DX technology is improving the healthcare experience. It's improving the efficiency of care, not just for chronic disease, but also for even primary care. Some of our largest U.S. clients are also primary care doctors and nurses who use Cloud DX to reduce the burden of chronic illness and make sure that their chronic disease patients don't have to go back to hospital or don't be... or not rather, readmitted to hospital. That is a huge, huge impact of virtual care using Cloud DX. Here's an interesting question. In our Q3 financials, salaries and wages were reduced by approximately 40%. How are we able to progress innovation, support, and expanding customer base with a reduced headcount? And this is something we're actually quite proud of. As I showed in the graphs earlier, patient numbers are expanding, the onboarding process is getting more efficient, revenues are climbing, subscription revenues are up 75%. We're managing this on a very tight team, and part of it is constant workflow improvement. Part of it is using automation as at its very best. Part of it is working with our partners, including the ones we've mentioned, Medtronic and Teladoc, but also with our largest customers, to reduce the workload, if you will, and improve the workflow. We're doing that on a constant, constant, constant basis. You will see over time, as Cloud DX expands and grows and becomes profitable and gets bigger and bigger, especially across the U.S., that our headcount, of course, will eventually creep up. But the ratio of increase in headcount to increase in subscription revenue is night and day. That is driving a steady increase in gross profit. So if you look back on our financial statements, you'll see quarter after quarter, Cloud DX gross profits have been climbing. So thank you for that question. Question about the... You know, what's going on in Africa with Accuscreen? So that's a great question. And so the fight against tuberculosis using new technology is something that has been ongoing for many years. The pandemic really slowed things down. When we first began the Accuscreen trials, we began that before the pandemic, and the trials took place during the pandemic, which made them more complicated. The trial ended, and the data began to be processed at the tail end of the pandemic. We're now at the point where we're expanding our footprint across Africa. The next project, TB Sequel, is actually taking place in four countries across Africa, and we're getting closer and closer to large, full-scale deployments. The reason we're able to do that is because the Accuscreen technology exceeds the WHO standard of specificity and sensitivity for a community screening tool for active TB. It's most often compared to a chest X-ray as the frontline screen for tuberculosis. Changing the entire workflow of a public health organization from point of care in the clinic chest X-rays to out in the field, cell phone-based software technology is an ongoing transition that's taking as much as it's gonna take. But the important part is the technology works. The need has never been smaller. Tuberculosis continues now to be the most deadly disease in the world. As a respiratory disease, it's now exceeding COVID again. And so our work in this field is not only changing the state-of-the-art, but it's also beginning to affect thousands and thousands of lives. And one day, we hope it will impact literally millions of lives. So the work continues, but it is accelerating, and that's very exciting. Let's see. Lots of questions still coming here. How are we doing for time? We still got some time. Okay, let's see. Here's a question on two... There's a two-part question here. First question: Is there a demand for glucose monitoring? And, the answer is that yes, Cloud DX's technology does monitor glucose using a third-party glucose meter that is produced by more than one, more than one company, actually. That is one of the features we're tracking in our dashboard. Glucose, or diabetes and glucose deficiency is a comorbidity for a number of different conditions that our clinicians are caring for patients. And then a follow-up question from the same investor is: Can we speak to actual numbers rather than percentages of growth? Obviously, we have not released our 2023 year-end financials yet, of course. We're just in the first couple of weeks of January. So we can speak to published financials in September, and the revenues that we announced in September were roughly CAD 1.4 million, but also showed these percentage changes from previous quarters and previous times... So the easiest way to sort of estimate revenue for 2023 is just to apply those percentages to that CAD 1.4 million number. And you know, I can't, I can't announce a firm number yet because we have an audit coming up, and of course, we don't have those those numbers released yet. When we speak to the contract signed in the first part of January here, again, you'll be able to see in the press releases roughly what percentage of you can expect of those contract announcements to be upfront dollars in the form of hardware purchases and in the first year of the contract, versus long-tail subscription revenue. As the next few of these investor presentations come along and more announcements are made, I'll be able to speak in greater detail to the actual numbers we can expect looking for in 2024. So stay tuned on that one. There's a question here about... Let's see. Wow, this is a great question, and it's a question from an investor that is very challenging for a CEO to answer. You know, with regards to all this great news announcements and all the announcements of growth and announcements of differentiation and competitive advantage, can we predict where the stock price is gonna go? And obviously, we can't. There's no way for me to say with certainty at any point where the stock price will go. But having said that, what we're trying to do here at Cloud DX is build the best company we can and grow as fast as we can. And we believe that if we continue to get the news out, continue to interface with investors, go to the conferences, speak up about our growth, talk about our advantages, the investment community will begin to hear our message, and at that point, we expect to see some changes in our share price. You know what? It's a market. We're just gonna keep selling, we're gonna keep growing, we're gonna keep building this subscription base, and we're gonna communicate as much as we can about our success. So that's our goal. Here's a great question from a, probably a physician investor. The need for the cough analysis, if you can tell the difference between viral and bacterial, would be huge. So that's the kind of scientific question I'd love to get into over a cup of coffee, you know. The way our cough analysis technology works is very much like the way ChatGPT works. It's the same idea of generative AI and large modeling of a neural network or large modeling of a convolutional network. So basically, in a nutshell, we collect thousands and thousands, and eventually, it will be millions and millions of the sound that's of cough sounds, people coughing. People who are healthy, who are just coughing because we ask them to cough, and people who are coughing because they have a respiratory illness. We know from earlier studies we've done with that technology, that we can actually differentiate seven different respiratory diseases, even at this early stage. The technology holds out the promise to be able to very accurately diagnose very specific respiratory illnesses, because the sounds are changed by the level of infection in the lungs, the level of inflammation in the throat, and so on. And just as we see with AI technology all over the world, it's changing at a very rapid pace. So without publishing a peer review paper on the subject, I can say that the promise of Cloud DX technology is to begin to differentiate from more and more different kinds of diseases. I think you know, everyone, this is one of the reasons Pfizer paid $116 million for our competitor. It's because this technology has tremendous promise. So, stay tuned on that one. Let's see. Let me see here. How quickly will Cloud DX get into the not only remote patient monitoring, but also adding management by allowing Cloud DX to address the shortages of cardiologists? In other words, how soon will the AI get to helping doctors make better management decisions, or to audit if improper meds are being used, et cetera? Thank you for that question. That is a great question. So addressing the need for clinical decision support, which is what this person is asking about, giving clinicians and especially physicians superpowers to be able to determine how a patient's gonna turn out based on all the data available on that patient in that moment. That is one of the core competencies of Cloud DX IP. So going back to our patent family, one of the series of patents that we have, and this is a series that was just added to yesterday, our newest patent meets this need. We synthesize and analyze all the data that comes in from our Vitaliti device, our Pulsewave device, our survey engine, and patient behavior patterns, and so on. Our AI software looks at all those permutations. They're very, very, very high frequency data streams, high frequency ECG streams, the actual raw signal from the pulse oximeter, called the PPG signal, and so on. So they have a tremendous amount of information in them. What we've patented is the ability for our technology to determine whether a patient has ingested medication and whether that medication is actually working and having the downstream effect that's expected. Our analytics engines are now building models that are designed to predict patient outcomes based on what we know now. In other words, of the 20,000 patients we're gonna study with Vitaliti, the massive study that's about to launch, how did all those patients work out? Did they get better? How fast did they get better? What was their experience along the way? That model will allow us to then take data from today and predict what's gonna happen to a patient in days or even weeks. That knowledge is what's going to make the healthcare industry enormously more efficient. It's gonna deliver better care, reduce the stress on doctors and nurses. All of that is being driven by the innovation at Cloud DX. So that is at the heart of what we do, and that's why that was a really great question. An interesting question on convertible notes. So if you go back and you read all of our press releases with regards to the money we raised using convertible notes, you'll see our convertible notes converted into common stock. There are no preferred share classes of stock at Cloud DX, but again, because those notes are majority-owned by insiders, then they're gonna be converted into stock and held. Insiders have the same common stock as all investors are purchasing on the market. Okay. The questions keep coming, so we'll keep going for another couple of minutes. How soon will the tuberculosis product be able to commercialize, and what will the model be? The commercialization of the product is around the corner because it's at the point now where it's already being used in larger scale field trials. It's the kind of software model that will be acquired or be purchased by public health agencies, governments, and even potentially large multinational companies that do a lot of their own internal healthcare. If you think about the company nurse in a large industrial complex, or a mine, or a commercial trucking company, these are companies where the health of their workers directly affects the bottom line, where a disease like tuberculosis can be devastating, and where a very simple, accurate screening tool that you can put on the cell phone that a nurse can use will make a tremendous difference. So again, Accuscreen is a smartphone app. It runs on the least expensive Android phones available in the developing world, and the model is one of two models. The first model is a public health nurse who is empowered with the technology to go out into the field and screen everyone in a village who has any kind of cough to determine which one of those folks actually has TB. That's a screening tool that would then result in that person being brought in for a definitive test, a blood test, or a sputum test, that confirms the TB diagnosis and the strain of TB, 'cause that's then what tells the doctors which medication to give that patient. But we've added a feature to Accuscreen that's very exciting. We've added a medication adherence feature, and this is part of one of the studies we're doing right now, which is called Video-Observed Therapy. So the software is not only smart enough to tell whether the person has a cough, but it's also gonna monitor whether the person has taken their TB medication. TB is a disease that is 100% curable. There's actually no reason that anyone on Earth should have TB, because it's not only curable, it's very inexpensive to cure. The drugs are generic. They cost pennies. What stops TB from being cured is the difficulty in screening folks who live far away from clinics, folks who are living in developing countries that have low access to healthcare. A simple, cheap smartphone that can detect tuberculosis and other diseases like that is gonna change the game. So the model, first of all, starts with public health departments deploying it into the field, improving the screening. They say if you read about TB, you'll see that there's approximately 3 million people every year with active TB who are never diagnosed. So our first mission is to diagnose those missing millions, the missing millions. But a further iteration of the technology could go as far as becoming an app you can download or an app that even comes with your cell phone. Imagine if you lived in a developing country. The cell phone company there has an app, a health app, that comes with your phone, part of your subscription, and it's capable of screening you and telling you whether or not you're at risk of TB and encouraging you to gain access to those public health resources immediately with the privacy and security of your own personal phone. So that is a model that would be a, you know, a subscription model through a cell phone product. That's another way to access the large populations that are at risk for tuberculosis. So there's more than one way we're, we're gonna tackle this. There's more than one way we're gonna get Accuscreen into the world. And we were fortunate we were able to attend the World Lung Health Union conference in Paris just a few months ago. We actually delivered some of the results from one of our studies at that conference, and we also had a chance to meet some public health officials from all over the world. So our technology, Accuscreen, is now on the radar at some of the largest public health organizations, and we're beginning conversations with folks like the WHO and the UN, who has the UN Sustainable Goals, one of which includes the eradication of tuberculosis. So you're gonna hear a lot more news about Accuscreen and, and the Cloud DX TB product coming up. A couple of folks along the way here have been asking about or not asking, actually, not asking questions, but offering information and offering advice. I just want to say we will get back to you by email with regards to some of the points you're making, introductions you want to make, folks that you think we can work with. We really appreciate all of that. Let me see here. There's a question about convertible debt. Again, happy to answer questions about convertible debt. So just to be clear, again, our convertible notes convert into common shares. The majority of them are owned by insiders. The expectation is they will convert their, their note to shares and hold their shares. When you look at the way we've structured our convertible debt, it matures at various times over the next two to three years, so that there's not one big maturity event coming up. But-... Even in the very near future, we're going to start seeing the interest expense from those notes being converted into stock, and then that stock being held by insiders. Okay. Lots of questions about Accuscreen and TB. One investor asked about the Gates Foundation. Definitely, we've had conversations with all the folks that are working in the TB space, and the funding available for different TB studies is something that we're working towards accessing. And as you know, Cloud DX, we're very good at accessing grant funding. We've done that many, many times. So that's definitely going to be a source of growth from the point of view of getting that out there. An interesting question here on patients here. Are there any data on the frequency of patient fall off or off-boarding due to problems, compliance, or understanding? And if so, are the resources to manage getting those dropouts back on remote watch, along with addressing the issues that lead to patient use difficulty? You know, I'm really pleased to answer this question because this is one of the absolute strengths of Cloud DX and one of our core, core differentiators. We have the highest compliance numbers in the industry, and we have a very specific set of compliance, automated compliance tools built into our platform. For example, when a patient is meant to take their readings, their doctors prescribe Connected Health. Their readings are meant to be taken on a daily basis. Our software is smart enough to notice immediately if a patient has not taken the reading they were supposed to take, and then we contact the patient. We're actually automating that process more and more. But right now, it's something that we do every single day to find out whether the reason they're not taking the reading is because of a technical issue, which we then solve, because of an issue with using the software, which we then re-educate the patient. And frankly, in some cases, we find that the patient needs escalation to the clinician, because the reason they're not taking the readings is they're in distress. And in fact, anecdotally, lives have been saved many times because we reach out immediately when we notice that a patient is not compliant with their care plan instructions. We do this better than anybody else in the business, and for that reason, the amount of patient drop-off we have is almost negligible. In fact, the most common reason a patient stops using their Cloud DX technology is because they're admitted to hospital, because, of course, we're dealing with quite sick people. So this is something that we do really, really well, and we're happy to talk about that. It's one reason why we keep winning these giant RFPs and provincial contracts. It's one reason why our longest-standing clients extend their contracts for years and years and years. Because they know that once a patient is on Cloud DX, they're gonna use the system, and they're gonna get the care they need. And I will also point out that in the United States, that compliance leads directly to reimbursement. So this also drives our U.S. business, because we can prove to our U.S. customers that our patients are compliant, and therefore, they're gonna get paid. Boy! Okay, I think we're coming to the end now of our question and answer period. If anybody has any further questions, please go ahead and just email the email on the investors, investor deck, or go to our website and fill out t he contact form. We'll do our very best to get back to everyone. And thank you again very much for all of your interest and all of the terrific questions. And please stay tuned for additional news from Cloud DX in the coming weeks and months. And if you get a chance, please see our other presentations. Thank you, everybody.